|Alexza Pharmaceuticals Inc.|
2091 Stierlin Court
United States - Map
Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The companys product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Its lead product, ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The companys product candidate in development, AZ-002 (Staccato alprazolam), is indicated for the treatment of acute repetitive seizures. It has strategic collaborations with Grupo Ferrer Internacional S.A. and Teva Pharmaceuticals USA, Inc. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.
|Mr. Thomas B. King ,
Chief Exec. Officer, Pres and Director
|Mr. Mark K. Oki CPA,
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
|Mr. Robert A. Lippe ,
Chief Operations Officer and Exec. VP of Operations
|Dr. Tatjana Naranda Ph.D.,
VP of Bus. Devel. and Global Alliance Management
|Dr. Edwin S. Kamemoto Ph.D.,
Sr. VP of Regulatory Affairs
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|